chemotherapyDose intensityStem-cell supportAs have many other chemosensitive tumors, small-cell lung cancer (SCLC) has a well-documented chemotherapy dose-response relationship. However, a relationship between dose and survival has not yet been established. The effect of dose on survival should be ...
Small cell lung canceraccounts for approximately 13% of all lung cancers and occurs primarily in smokers. Small cell lung cancer is characterized by early metastases and rapid growth. While initially very responsive to both chemotherapy and radiation therapy, the majority of patients will have ...
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.What are the subtypes of NSCLC?Squamous cell carcinoma is found in cells that line the airways of the lungs. It is usually found in the middle of the lung. Adenocarcinoma is found in cells that produce mucus. It...
A Santoro,L Maiorino,M Santoro - 《Lung Cancer》 被引量: 38发表: 1994年 Is more better? Chemotherapy for patients with extensive-stage small-cell lung cancer Examines the desirability of chemotherapy for patients with extensive-stage small-cell lung cancer. Adaptation of a four-drug regimen as...
For more than three decades, care for small-celllung cancer(SCLC) remained mostly the same. That’s changing now -- doctors have a new option called immunotherapy. This line of treatment uses your body’s own immune system to fight cancer. ...
National Cancer Center Hospital, Tuskiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan Small-cell lung cancer (SCLC) accounts for approximately 15% of all cases of lung cancer and is a particularly aggressive form of lung cancer characterised by a poor prognosis, rapid tumour growth, and early me...
cell lymphoma, diffuse large B-cell lymphoma (DLBCL),10inflammatory myofibroblastic tumor,11and non-small cell lung cancer (NSCLC).12Fusion of echinoderm microtubule-associated protein-like 4 withALK(EML4-ALK) in NSCLC was identified in 2007 by Soda et al.12this rearrangement of theALKgene has...
Small-cell lung cancer spreads quickly. From 67%-75% of people who develop small cell lung cancerwill have spread the SCLC outside of the lung to other parts of the body at the time of initial diagnosis. Small-cell lung cancer responds well to chemotherapy (using medications to kill cancer...
(HealthDay)—Tecentriq (atezolizumab) has been approved by the U.S. Food and Drug Administration to treat adults with extensive-stage small cell lung cancer (ES-SCLC). The drug has been approved as a first-line treatment for the disease, to be used in combination with thechemotherapy drugs...
Specimens from 45 patients with previously-untreated non-small cell lung cancer (NSCLC) were tested for in vitro chemosensitivity to ten drugs utilising the DiSC assay, which measures cell kill in the total (largely non-dividing) tumour cell population. Thirty-five assays were successful and 25 ...